Nicholas W. Choong, MD
Assistant Professor of Medicine
Dr. Choong joined the faculty at the Medical College of Wisconsin in July 2007. After completing medical school at McGill University, Montreal, Canada, he went on to train in Internal Medicine at the Mayo Clinic in Rochester, MN. Subsequently, he completed his Hematology-Medical Oncology fellowship at the University of Chicago Medical Center in Chicago, IL.
Dr. Choong’s practice is focused on head, neck and thoracic malignancies. Apart from spearheading the development of the Pulmonary Lung Cancer Collaborative Clinic, which focuses on the multidisciplinary management of patients with lung cancer, he is active in conducting clinical trials in head, neck and thoracic malignancies, and has published numerous peer-reviewed scientific articles, abstracts and book chapters. Apart from being Board Certified in Internal Medicine and Medical Oncology, he has received several awards including the National Lung Cancer Partnership Award and the American Society of Clinical Oncologist Foundation Merit Award.
Selected Publications
1. Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin C, Hoffman PC, Krauss SA, Szeto L, Mauer AM. Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2008;3(1):59-67.
2. Choong NW, Vokes EE. Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer. CA Cancer J Clin. 2008;58(1):32-53
3. Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer 2007;8 Suppl 2:S52-60.
4. Choong NW, Cohen EE. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 2006;57(1):25-43.
5. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol 2006;3(1):50-7
6. Choong NW, Cohen EE. Forthcoming receptor tyrosine kinase inhibitors. Expert Opin Ther Targets 2006;10(6):793-7.
7. Choong NW, Mauer AM, Hoffman PC, Rudin CM, Winegarden JD, 3rd, Villano JL, et al. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2006;1(3):245-51.
8. Choong NW, Vokes EE. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 2005;7 Suppl 3:S98-104.
9. Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets 2005;9(3):533-59.